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The effects of buserelin
microparticles on ovarian
function in healthy women
B. H. Meyer, F. O. Muller, N. de la Rey, H. G. Luus,
B. Rosenkranz
Objective. To investigate the tolerance, pharmacokinetics
and pharmacodynamJcs of the microparticle fonnulation of
buserelin, when it wasaaministered subcutaneously.
Design. Asingle-blind, randomised, parallel-group design
was used to investigate the duration of suppression of
ovarian function associated with doses of 1,8, 3,6 and 7,2 mg
buserelin administered subcutaneously as microparticles.
Setting. The study was carried out at the Hoechst
Research Centre for Clinical Pharmacology, Department of
Pharmacology, University of the Orange Free State,
Bloemfontein.
Patients. Thirty-two healthy premenopausal female
volunteers aged between 19 and 39 years and weighing
between 52 and 85 kg completed the study.
Outcome measures. Serum progesterone and oestradiol
concentrations were measured twice weekly until normal
ovarian function resumed, Le. when serum progesterone
concentrations increased to at least 8 nmoVI (a sign of
ovulation) and oestradiol concentrations increased to
values above 300 pmol/l. Serum and urinary
concentrations of buserelin were measured at the same
times as those of progesterone and oestradiol.
Results. Doses of 1,8,3,6 and 7,2 mg elicited
anovulation for mean periods of 52, i1 and 113 days and
suppressed ovarian production of oestrogen for 19, 38 and
69 days. Resumption of normal ovarian function occurred
when serum buserelin concentrations decreased to
between 0,03 and 0,05 lJg/ml. The correlation coefficient
between dose and duration of anovulation was 0,75; the
correlation coefficient between dose and duration of
suppression of oestrogen production was 0,76.
Conclusion. Apart from minor side-effects such as hot
flushes, vaginal spotting and acne, the compound was
tolerated well. We conclude that a good relationship exists
between dose and duration of suppression of ovarian
function. Doses of 3,6 - 7,2 mg buserelin should suppress
oestrogen production for approximately 6 - 9 weeks and
ovulation for 11 - 16 weeks.
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The luteinising hormone-releasing hormone (LHRH) agonists
are antigonadotrophic agents used to elicit reversible
gonadal suppression in gynaecology and oncology.'
Buserelin, which is one of the LHRH agonists, has been
tested in prostatic cancer patients and in patients with
mammary carcinoma! It can be administered as injections,
nasal sprays and implants and has recently been formulated
as microparticles to provide a subcutaneous depot with a
view to improved compliance. The peptide is encapsulated
in microparticles of polylactide co-polymer that can be
suspended in water prior to subcutaneous injection.
Buserelin microparticles are effective in rhesus monkeys,
and completely suppress follicular maturation and oestrogen
production for 4 - 6 weeks after a single dose of 3,6·mg.'
A long-lasting reversible hypogonadism was elicited in
women by intramuscular injection of the hypothalamic
releasing honnone, gonadorelin, in a microcapsule
fonnulation.' .
In another study gonadorelin microcapsules suppressed
the pituitary testicular axis for at least 50 days.' .'
Subjects and methods
The primary objective of the study was to identify the dose
of the microparticle formulation of buserelin that would
provide release of the drug sufficient to suppress ovarian
function for 4 - 6 weeks in humans. The secondary objective
was to investigate the tolerability of buserelin microparticles
in humans.
The study was conducted in accordance with the
requirements of good clinical practice, with the permission
of the Ethics Committee of the Faculty of Medicine of the
University of the Orange Free State; volunteers gave
informed consent.
During a control menstrual cycle preceding the
administration of buserelin microparticles normal ovarian
function had to be proved. Blood samples, for the
measurement of serum progesterone concentrations, were
taken on days 19, 23 and 26 of the cycle, and a progesterone
concentration of 8 nmoVI or more on any of these days was
considered proof of ovulation. Volunteers in whom ovulation
was not confirmed were excluded from the study.
Thirty-two healthy premenopausal women (age range
19 - 39 years; weight range 52 - 85 kg) completed this
single-blind, randomised study in 3 parallel groups.
Buserelin microparticles were administered as a single
dose, injected subcutaneously through a 22G needle into the
lateral abdominal wall. Doses were: group 1 (12 SUbjects) -
1,8 mg; group 2 (11 subjects) - 3,6 mg; group 3 (9 subjects)
- 7,2 mg. Medication was given on the second or third day
of the menstrual period following the control cycle.
Blood samples for measurement of serum oestradiol,
progesterone and buserelin concentrations were taken twice
weekly (Mondays and Thursdays) after injection; timing was
arranged so that blood samples were taken as consistently
as possible at the same time of day. SampleS for
determination of urinary buserelin concentrations were taken
early in the morning on the same days as the blood samples.
Twice weekly blood and urine sampling continued until
return of normal ovarian function was confirmed; a serum
progesterone concentration of at least 8 nmol/l was used as
a criterion of ovulation and a serum oestradiol concentration
above 300 pmo!ll as a sign of normal ovarian function.
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• Excluding one value of 21 days, the range was 62 • 99 days.
Results
Table I. Mean number of days after medication during which
serum progesterone concentration was below 8 nmolll (i.e.













Fig. 2. Mean serum oestradiol (--) and progesterone (- - -)
concentrations for doses of 1,8 ("), 3,6 (0) and 7,2 (#) mg buserelin.
Discussion
Fig. 1. Mean serum buserelin concentrations (--) and urinary
buserelin excretion per gram urinary creatinine (- - -) for doses of





Dose (mg) Days CV% Range
1,8 52 51,0 16,0 - 88,0
3,6 77 29,2 21,0 - 99,0'
7,2 113 13,9 91,0 - 144
Serum and urinary buserelin concentrations were measured
by means of a radio-immunoassay technique, and urinary
creatinine concentrations by means of an enzymatic method.
Serum progesterone and oestradiol concentrations were
measured by means of the Coat-a-Count (Diagnostic
Products Corporation) (detection limits: progesterone 0,3
nmol/I, 94 pg/ml; oestradiol 70 pmol/I, 20 pg/mI).
Apart from minor side-effects such as hot flushes, vaginal
spotting, acne and headaches the microparticles were
tolerated well.
The mean duration of suppression of serum progesterone
concentrations to values below 8 nmol/I and suppression of
serum oestradiol concentrations to values below 300 pmol/I
are shown in Tables I and 11. The mean serum buserelin
concentrations and urinary buserelin excretion (~g/g
creatinine) are shown in Fig. 1; the corresponding mean
serum progesterone and oestradiol concentrations for the
three doses are shown in Fig. 2.
Dose (mg) Days CV%
Table 11. Mean number of days after medication during which
serum oestradiol concentration was below 300 pmol/l (i.e.




• Excluding one value of 0 days, the range was 21 . 56 days.
Regression analysis of the dose of buserelin
microparticles and the duration of suppression of ovulation
(measured by the number of days that serum progesterone
levels were b~low 8 nmol/I) yielded a correlation coefficient
of 0,75. The correlation coefficient between dose and
duration of suppression of serum oestradiol concentrations
to values below 300 pmol/I was 0,76.
The end of the effect of buserelin on ovulation was
defined as the point in time when two consecutive serum
progesterone concentrations were above 8 nmol/l. The mean
serum buserelin concentrations associated with resumption
of ovulation and with oestradiol concentrations above 300
pmol/I are given in Table Ill.
Both the duration of suppression of ovulation and reduction
of oestradiol serum concentration correlated well with the
dose administered. Inhibition of ovarian function ceased
when buserelin serum concentrations fell below 0,04 ~g/ml
and urinary excretion of the compound fell below
approximately 0,4 ~g/g creatinine.
We conclude that the microparticle fonmulation of
buserelin was tolerated well, and that a good relationship
exists between dose administered and duration of
suppression of ovarian function. A dose of between 3,6 mg
and 7,2 mg of the microparticles should be ideal for
suppression ,of ovarian function and should suppress
oestrogen production for a period of between 6 and 9
weeks, and ovulation for between 11 and 16 weeks.
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